These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 12166360)
1. Low-molecular weight heparins - the mainstay of anti-coagulant therapy. Cardiovasc J S Afr; 2002; 13(2):80-2. PubMed ID: 12166360 [No Abstract] [Full Text] [Related]
2. A contemporary assessment of low-molecular-weight heparin for the treatment of acute coronary syndromes: factoring in new trials and meta-analysis data. Topol EJ Am Heart J; 2005 Apr; 149(4 Suppl):S100-6. PubMed ID: 16124950 [No Abstract] [Full Text] [Related]
3. Low molecular weight heparins in acute coronary syndrome. Creekmore F S D J Med; 2000 Jan; 53(1):21-3. PubMed ID: 10652862 [No Abstract] [Full Text] [Related]
4. Low-molecular-weight heparins and glycoprotein IIb/IIIa inhibitors with percutaneous coronary intervention in acute coronary syndromes. Shimpi RA J Invasive Cardiol; 2003 Aug; 15(8):460-5. PubMed ID: 12890880 [No Abstract] [Full Text] [Related]
5. Use of low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Fernandez JS; Sadaniantz A Med Health R I; 2001 Feb; 84(2):37-43. PubMed ID: 11272658 [No Abstract] [Full Text] [Related]
10. Low-molecular-weight heparins for the treatment of acute coronary syndromes. Wong GC; Giugliano RP Semin Vasc Med; 2003 Nov; 3(4):391-402. PubMed ID: 15199446 [TBL] [Abstract][Full Text] [Related]
11. The role of low-molecular-weight heparins in non-ST-segment elevation acute coronary syndromes. Nguyen-Ho P; Levine GN Panminerva Med; 2002 Jun; 44(2):115-22. PubMed ID: 12032429 [TBL] [Abstract][Full Text] [Related]
12. Quick, easy, and safe? On the use of low-molecular-weight heparins in cardioversion of atrial fibrillation. Stellbrink C Eur Heart J; 2006 Dec; 27(23):2742-3. PubMed ID: 17098755 [No Abstract] [Full Text] [Related]
14. Low-molecular-weight heparins in conjunction with thrombolysis for ST-elevation acute myocardial infarction. A critical review of the literature. Rubboli A; Ottani F; Capecchi A; Brancaleoni R; Galvani M; Swahn E Cardiology; 2007; 107(2):132-9. PubMed ID: 16864962 [TBL] [Abstract][Full Text] [Related]
15. Role of low-molecular-weight heparin in invasive management of non-ST-elevation acute coronary syndromes. Moser LR; Kalus JS Ann Pharmacother; 2004 Dec; 38(12):2094-104. PubMed ID: 15536140 [TBL] [Abstract][Full Text] [Related]
16. Dabigatran: new drug. Continue to use heparin, a better-known option. Prescrire Int; 2009 Jun; 18(101):97-9. PubMed ID: 19637411 [TBL] [Abstract][Full Text] [Related]
17. [Reperfusion after acute myocardial infarct with fibrinolytic therapy o combination reduced fibrinolytic therapy and a glycoprotein IIb/IIIa inhibitor: the GUSTO V study]. Franzosi MG Ital Heart J Suppl; 2001 Sep; 2(9):1034-6. PubMed ID: 11675828 [No Abstract] [Full Text] [Related]
18. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes. Cohen M J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722 [TBL] [Abstract][Full Text] [Related]
20. [Heparin in the treatment of unstable angina. Can the decrease of the molecular size increase its effectiveness?]. Panchenko EP Ter Arkh; 1998; 70(12):71-4. PubMed ID: 10067259 [No Abstract] [Full Text] [Related] [Next] [New Search]